<DOC>
	<DOCNO>NCT00710229</DOCNO>
	<brief_summary>Angiogenesis play key role development choroidal neovascularizations ( CNV ) age-related macular degeneration . Vascular endothelial growth factor ( VEGF ) important factor involve angiogenetic process eye . This forms basis new therapeutic intervention exudative AMD . Currently two drug approve FDA one drug use off-label . All drug administer intravitreally . The present study aim directly compare effect ranibizumab bevacizumab randomize control study patient neovascular AMD .</brief_summary>
	<brief_title>Manta Study : Avastin Versus Lucentis Age Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age â‰¥ 50 year Active primary recurrent subfoveal lesion CNV secondary AMD Prior treatment intravitreal drug study eye Prior treatment verteporfin photodynamic therapy study eye Prior treatment systemic bevacizumab Prior treatment intravitreal durg verteprofin photodynamic therapy nonstudy eye within 3 moth study entry Laser photocoagulation within 1 month study entry study eye Previous participation clinical trial within 1 month entry study Subfoveal fibrosis atrophy study eye CNV either two eye due cause AMD histoplasmosis pathologica myopia Retinal pigment epithelial tear involve macula study eye Any concurrent intraocular condition study eye could either require medical surgical intervention 12 month study period could contribute loss best correct visual acuity 12 month study period ( e.g . diabetic retinopathy , cataract , uncontrolled glaucoma ) . The decision exclusion base opinion local principal investigator . Active intraocular inflammation Vitreous hemorrhage study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>age relate macular degeneration</keyword>
	<keyword>Ranibizumab-Lucentis</keyword>
	<keyword>Bevacizumab-Avastin</keyword>
</DOC>